Literature DB >> 30214599

Intratibial injection of patient-derived tumor cells from giant cell tumor of bone elicits osteolytic reaction in nude mouse.

Leqin Xu1,2, Zhipeng Wu1, Zhenhua Zhou1, Xinghai Yang1, Jianru Xiao1.   

Abstract

There have been various reports in the literature of an in vivo model for giant cell tumor of bone (GCTB). However, few suitable animal models of GCTB have been established, due to the fact that GCTB contains three histologically different cell types. To the best of our knowledge, injection of patient-derived GCTB cells into bone environment has not been reported until now. In the present study, the biological behavior of GCTB cells in nude mice was investigated through intratibial injection of patient-derived GCTB cells. Patient-derived GCTB cells were obtained from 5 patients who had not undergone chemo- and radiotherapy. Once isolated, the cell suspension was injected into the tibias of nude mice. The growth process was monitored by weekly observation and photographic documentation using X-ray. Four months after injection, nude mice were sacrificed and the injected tibial samples were fixed, and further analyzed using micro-computed tomography (micro-CT), standard histology, tartrate-resistant acid phosphatase (TRAP) staining and mitochondrial immunofluorescence staining. X-ray, micro-CT and standard histology revealed osteolytic destruction in the proximal end of the tibia. TRAP staining identified TRAP-positive, osteoclast-like cells distributed in the bone marrow interface of the lesion area. Anti-human mitochondrial immunofluorescence staining confirmed that the surviving cells in the osteolytic destruction were of human GCTB cell origin. These findings indicate that intratibial injection of patient-derived GCTB cells may elicit osteolytic destruction in nude mice. The results of the current study present a novel animal model for GCTB, opening new perspectives to investigate this disease and develop therapeutic agents.

Entities:  

Keywords:  animal model; bone environment; bone lysis; giant cell tumor of bone; intratibial injection

Year:  2018        PMID: 30214599      PMCID: PMC6126149          DOI: 10.3892/ol.2018.9148

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  43 in total

Review 1.  Mimics on radiography of giant cell tumor of bone.

Authors:  Gregory S Stacy; Terrance D Peabody; Larry B Dixon
Journal:  AJR Am J Roentgenol       Date:  2003-12       Impact factor: 3.959

2.  Stimulation of osteogenic differentiation in stromal cells of giant cell tumour of bone by zoledronic acid.

Authors:  Tao Yang; Xiao-Fei Zheng; Mei Li; Xi Lin; Qing-Shui Yin
Journal:  Asian Pac J Cancer Prev       Date:  2013

3.  Pre-clinical mouse models of human prostate cancer and their utility in drug discovery.

Authors:  Serk In Park; Sun Jin Kim; Laurie K McCauley; Gary E Gallick
Journal:  Curr Protoc Pharmacol       Date:  2010-12

4.  Epidermal growth factor receptor signalling contributes to osteoblastic stromal cell proliferation, osteoclastogenesis and disease progression in giant cell tumour of bone.

Authors:  Peter Balla; Linda Moskovszky; Zoltan Sapi; Ramses Forsyth; Helen Knowles; Nick A Athanasou; Miklos Szendroi; Laszlo Kopper; Hajnalka Rajnai; Ferenc Pinter; Istvan Petak; Maria Serena Benassi; Piero Picci; Amalia Conti; Tibor Krenacs
Journal:  Histopathology       Date:  2011-09       Impact factor: 5.087

Review 5.  Characterization of cells from human giant cell tumors of bone.

Authors:  S R Goldring; A L Schiller; H J Mankin; J M Dayer; S M Krane
Journal:  Clin Orthop Relat Res       Date:  1986-03       Impact factor: 4.176

6.  Matrix metalloproteinase activity inactivates the CXC chemokine stromal cell-derived factor-1.

Authors:  G A McQuibban; G S Butler; J H Gong; L Bendall; C Power; I Clark-Lewis; C M Overall
Journal:  J Biol Chem       Date:  2001-09-24       Impact factor: 5.157

7.  Identification of differentially expressed genes and their subpathways in recurrent versus primary bone giant cell tumors.

Authors:  Shuxin Chen; Chunquan Li; Bingli Wu; Chunlong Zhang; Cheng Liu; Xiaoxu Lin; Xiangqiao Wu; Lingling Sun; Chunpeng Liu; Bo Chen; Zhigang Zhong; Liyan Xu; Enmin Li
Journal:  Int J Oncol       Date:  2014-06-18       Impact factor: 5.650

8.  Expression of preosteoblast markers and Cbfa-1 and Osterix gene transcripts in stromal tumour cells of giant cell tumour of bone.

Authors:  L Huang; X Y Teng; Y Y Cheng; K M Lee; S M Kumta
Journal:  Bone       Date:  2004-03       Impact factor: 4.398

9.  Evidence for an autocrine/paracrine role for interleukin-6 in bone resorption by giant cells from giant cell tumors of bone.

Authors:  Y Ohsaki; S Takahashi; T Scarcez; A Demulder; T Nishihara; R Williams; G D Roodman
Journal:  Endocrinology       Date:  1992-11       Impact factor: 4.736

10.  Iterative curettage is associated with local control in giant cell tumors involving the distal tibia.

Authors:  Saleh A AlSulaimani; Robert E Turcotte
Journal:  Clin Orthop Relat Res       Date:  2013-04-09       Impact factor: 4.176

View more
  3 in total

Review 1.  Role of cancer stem cells in the development of giant cell tumor of bone.

Authors:  Abdul Rouf War; Kai Dang; Shanfen Jiang; Zhongwei Xiao; Zhiping Miao; Tuanmin Yang; Yu Li; Airong Qian
Journal:  Cancer Cell Int       Date:  2020-04-25       Impact factor: 5.722

2.  Serglycin induces osteoclastogenesis and promotes tumor growth in giant cell tumor of bone.

Authors:  Yunfei He; Dongdong Cheng; Cheng Lian; Yingjie Liu; Wenqian Luo; Yuan Wang; Chengxin Ma; Qiuyao Wu; Pu Tian; Dasa He; Zhenchang Jia; Xianzhe Lv; Xue Zhang; Zhen Pan; Jinxi Lu; Yansen Xiao; Peiyuan Zhang; Yajun Liang; Qingcheng Yang; Guohong Hu
Journal:  Cell Death Dis       Date:  2021-09-23       Impact factor: 8.469

3.  H3.3 G34W Promotes Growth and Impedes Differentiation of Osteoblast-Like Mesenchymal Progenitors in Giant Cell Tumor of Bone.

Authors:  Sima Khazaei; Nicolas De Jay; Shriya Deshmukh; Liam D Hendrikse; Wajih Jawhar; Carol C L Chen; Leonie G Mikael; Damien Faury; Dylan M Marchione; Joel Lanoix; Éric Bonneil; Takeaki Ishii; Siddhant U Jain; Kateryna Rossokhata; Tianna S Sihota; Robert Eveleigh; Véronique Lisi; Ashot S Harutyunyan; Sungmi Jung; Jason Karamchandani; Brendan C Dickson; Robert Turcotte; Jay S Wunder; Pierre Thibault; Peter W Lewis; Benjamin A Garcia; Stephen C Mack; Michael D Taylor; Livia Garzia; Claudia L Kleinman; Nada Jabado
Journal:  Cancer Discov       Date:  2020-09-23       Impact factor: 38.272

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.